Key Highlights
- Personalis shares are trading up 8.48% today, extending gains as investors digest recent results and merger news.
- Clinical test volume surged 199% year-over-year to 10,384 tests in the second quarter.
- Q2 revenue grew 30% to $22.4 million, even as the company suspended standalone guidance ahead of its pending merger.
- Personalis is set to be acquired by Tempus AI, with the deal under close watch this week.
What's Happening With Personalis Stock Today?
Personalis (NASDAQ:PSNL) shares are climbing further today as investors continue to digest a strong second-quarter report alongside the pending Tempus AI merger. Clinical test volume surged 199% year-over-year to 10,384 tests, while Q2 revenue grew 30% to $22.4 million. The stock's rally reflects continued momentum following the July 20 merger agreement with Tempus AI, under which Personalis will cease providing standalone guidance.
Personalis is a commercial-stage precision oncology company headquartered in Fremont, California, that develops and markets advanced cancer genomic tests and analytics built on its proprietary ImmunoID NeXT platform, serving biopharmaceutical firms, academic and cancer research institutions, and government agencies.
Merger Backdrop and Sector Strength
The stock's rally also reflects continued momentum tied to the merger with Tempus AI, under which the standalone guidance suspension shifts investor focus toward deal closing rather than independent quarterly targets. The pending combination brings together Personalis's genomic testing capabilities with Tempus AI's broader precision medicine and data platform.
The move also fits into broader healthcare sector strength this week, with diagnostics peers GeneDx Holdings (NASDAQ:WGS) and Agilon Health (NYSE:AGL) also posting notable gains as investors reward companies showing accelerating volume growth and improving profitability trends.
Conclusion
Personalis shares are rising today as strong second-quarter test volume and revenue growth combine with continued investor attention on the pending Tempus AI acquisition. The stock's move also reflects broader momentum across the diagnostics and genomics space this week.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...